Benutzer: Gast  Login
Titel:

A limited number of 5-azacitidine cycles can be effective treatment in MDS.

Dokumenttyp:
Journal Article
Autor(en):
Müller-Thomas, C; Schuster, T; Peschel, C; Götze, KS
Abstract:
Hypomethylating agents, such as 5-azacitidine (5-AZA) and 5-aza-2'-deoxycytidine (decitabine), have recently been approved for the treatment of myelodysplastic syndromes (MDS). Several randomized trials have shown favorable results concerning response rate, survival, transformation to acute leukemia, and quality of life. In these trials, treatment was administered continuously until progression. In the retrospective study presented here, we evaluated the outcome of patients with higher risk MDS...     »
Zeitschriftentitel:
Ann Hematol
Jahr:
2009
Band / Volume:
88
Heft / Issue:
3
Seitenangaben Beitrag:
213-9
Sprache:
eng
Volltext / DOI:
doi:10.1007/s00277-008-0583-8
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/18696067
Print-ISSN:
0939-5555
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Medizinische Statistik und Epidemiologie
 BibTeX